Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Jan 5

Brad Good has been an endorsed Squarespace Expert since the beginning and has been working on the platform since 2008. He has helped hundreds of Squarespace customers with their websites.

http://www.bradgood.net

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

89bio Provides Business Update and Outlook for 2023